Annate Bitherapeutics

Annate Bitherapeutics Wins Top Award at UGA Field to Fund: Where Innovation Meets Opportunity

2025-10-03T00:00:00+00:00

Annate Bitherapeutics is proud to announce that CEO Eric DeJesus, PhD, received top recognition and a $2,500 award at the University of Georgia’s Field to Fund: Where Innovation Meets Opportunity event, hosted by the UGA Innovation District and Innovation Gateway. The competition brought together leading entrepreneurs and researchers from UGA and the University of Kentucky to present cutting-edge technologies addressing major scientific and medical challenges.

Dr. DeJesus’s pitch showcased Annate’s novel bispecific antibody platform that harnesses the human innate immune system for the treatment of multiple myeloma. By redirecting a naturally occurring component of the immune complex, Annate’s therapeutic approach targets and eliminates malignant cells with precision, opening new possibilities for treating resistant cancers.

The event featured dynamic discussions led by Jay Bailey (President & CEO, Russell Innovation Center for Entrepreneurs) and Keith Marshall (Co-CEO, The Players’ Lounge), followed by pitches from four high-impact startups. Judges included distinguished alumni Michael Bowling, Stacy A. Chick, Robert Orr, and Anath Qualls.

Annate Bitherapeutics was awarded the evening’s top prize, sponsored by Hutchison PLLC, which also provided each team with a complimentary hour of legal consultation.

“Events like Field to Fund show what’s possible when universities, investors, and innovators come together to celebrate entrepreneurship and push science forward,” said Dr. Eric DeJesus.

The evening highlighted the power of collaboration between academia and industry, reinforcing Annate’s role in translating academic innovation into transformative cancer treatments.

Read the full story at the University of Georgia’s Innovation site:
Inspiration and Innovation in Action: UGA Hosts Field to Fund

CEO Eric DeJesus Wins 2025 UGA Quick Pitch Event

2025-09-20T00:00:00+00:00

We are excited to announce that Eric DeJesus, PhD, CEO and Founder of Annate Bitherapeutics, has won the 2025 UGA Quick Pitch Event. This competition, hosted annually by the University of Georgia, highlights innovative entrepreneurs and provides a platform for researchers and startups to showcase their ideas in a fast-paced pitch format.

Dr. DeJesus’s winning presentation emphasized Annate’s pioneering work harnessing the innate immune system to develop new therapies for multiple myeloma and pancreatic cancer.

Winning the Quick Pitch Event not only recognizes the strength of our science and business vision but also connects Annate to expanded mentorship, networking, and visibility within the UGA innovation community.

We are honored to be acknowledged by UGA and remain committed to advancing transformative cancer therapeutics from the lab to the clinic.

For more information about the Quick Pitch program, visit:
UGA Quick Pitch

Annate Bitherapeutics Technology Entered into UGA InPart Portal

2025-09-15T00:00:00+00:00

Annate Bitherapeutics is proud to announce that our technology has been officially listed on the University of Georgia’s InPart portal, a digital platform designed to connect groundbreaking research and innovations with potential industry partners.

The InPart portal showcases UGA-developed technologies to foster collaboration, licensing, and translational impact. By featuring Annate’s approach to next-generation cancer therapeutics, this listing increases visibility with pharmaceutical, biotech, and investment communities actively seeking new opportunities.

This milestone represents another step forward in our mission to translate academic research into clinically meaningful therapies. We look forward to the collaborations and partnerships this exposure may generate as we continue to advance our platform.

Learn more on the UGA InPart portal:
Annate Bitherapeutics on UGA InPart

Annate Bitherapeutics Wins Pitch Competition at Georgia Life Sciences Summit

2025-08-27T00:00:00+00:00

At the 2025 Georgia Life Sciences Summit Startup Showcase, Annate Bitherapeutics was honored to be named the pitch competition winner. This recognition underscores the strength of our innovative science and the promise of our mission to deliver next-generation cancer therapeutics.

As part of the award, Annate earned exclusive one-on-one time with the BioTech Execs Network, providing invaluable opportunities to refine our strategy, connect with seasoned industry leaders, and accelerate our path toward clinical and commercial impact.

The Georgia Life Sciences Summit continues to be the premier gathering for the state’s bioscience and medtech community, spotlighting groundbreaking research and emerging companies. Winning the Startup Showcase represents a major milestone for Annate Bitherapeutics, and we are deeply grateful to Georgia Bio and the wider life sciences community for this opportunity to share our vision.

For more information about the Summit and the Startup Showcase, visit:
Georgia Life Sciences Summit

Annate Bitherapeutics to Present at Georgia Life Sciences Summit 2025

2025-08-20T00:00:00+00:00

We are honored to announce that Annate Bitherapeutics has been chosen to participate in the Startup Showcase at the 2025 Georgia Life Sciences Summit, taking place August 26–27 at the Sandy Springs Performing Arts Center in Atlanta.

This opportunity places Annate alongside Georgia’s most promising life sciences ventures, providing exposure to a distinguished audience of industry leaders, investors, scientists, and policymakers. The Startup Showcase is a central feature of the Summit, designed to elevate emerging technologies and foster critical industry connections.

The Georgia Life Sciences Summit is the state’s premier gathering for the bioscience and medtech community. It brings together professionals from industry, academia, and government to explore major trends in scientific research, commercialization, financing, and policy.

We’re thrilled to represent Annate Bitherapeutics at this important event—and we look forward to amplifying our impact through these meaningful conversations and collaborations.

Eric DeJesus Featured by ARCS Foundation and ARCS Forward

2025-06-14T00:00:00+00:00

The ARCS Foundation recently spotlighted Eric DeJesus, PhD, Founder & CEO of Annate Bitherapeutics, for his groundbreaking work in cancer immunotherapy. As an ARCS Scholar Alum, Dr. DeJesus has built on his academic foundation to launch Annate’s therapeutic platform, which leverages innate immunity to fight multiple myeloma and pancreatic cancer.

🎥 Watch the Talk

Dr. DeJesus presented at the June 2025 ARCS Forward event, delivering a talk titled Reducing the Impact of Cancer. In this presentation, he outlines the scientific basis of Annate’s therapies and the company’s vision for addressing unmet needs in oncology.

(Click image to watch the video on YouTube)

📖 Read the Feature

Alongside the event, ARCS published a feature article on Dr. DeJesus, highlighting his journey from ARCS Scholar to biotech entrepreneur:
ARCS Scholar Alum Eric DeJesus Pushes Boundaries in Cancer Treatment

Together, the feature article and the ARCS Forward talk showcase how Annate Bitherapeutics is translating innovative research into a new generation of cancer treatments.

Eric DeJesus to Present at ARCS Forward: Reducing the Impact of Cancer

2025-06-10T00:00:00+00:00

Eric DeJesus, PhD, scientist, entrepreneur, and Founder & CEO of Annate Bitherapeutics, will present at ARCS Forward on June 10, 2025 in a live Zoom session titled “Reducing the Impact of Cancer.” He’ll explore how his team is harnessing a novel component of the innate immune system to selectively target and kill cancer cells — with programs aimed at multiple myeloma and pancreatic cancer.

ARCS Forward events are designed as personal, intimate dialogues between ARCS members, scholars, and leading STEM experts. Dr. DeJesus’s participation underscores the translational promise of his work and the broader mission of turning research into treatments.

To learn more about the event or view recordings, visit the ARCS Forward page and browse the playlist on the ARCS Foundation YouTube channel.

Event details: ARCS Forward — “Reducing the Impact of Cancer”
ARCS Foundation YouTube channel: ARCS Forward playlist (available there)

Sources: Event listing from ARCS Forward (June 10, 2025) :contentReference[oaicite:1]{index=1}

Annate Bitherapeutics Represents UGA at Southeastern Venture Showcase

2025-06-02T00:00:00+00:00

Annate Bitherapeutics was featured by the University of Georgia for representing UGA at the inaugural Southeastern Venture Showcase (SVS) in Nashville, where a select cohort of research-based startups presented to the venture community. The recognition reflects our progress translating university-born innovations toward patient impact and commercial readiness.

SVS convenes investors, technology experts, and founders from universities and federal labs across the Southeast to accelerate the path from lab discovery to market adoption. Being showcased alongside peer innovators reinforces the momentum behind our platform and expands our network for future partnerships and fundraising. Learn more from UGA’s coverage and visit the official SVS site for event details.

UGA news: Annate Bitherapeutics represents UGA at Southeastern Venture Showcase
Event site: Southeast Venture Showcase

Annate Bitherapeutics Chosen to Pitch at Southeast Venture Showcase

2025-02-05T00:00:00+00:00

Annate Bitherapeutics is proud to announce that we have been selected by a judging panel of over 70 investors and serial entrepreneurs to present at the inaugural Southeast Venture Showcase (SVS). The SVS is a transformational event that empowers research universities and federal laboratories across the Southeast to showcase their most promising technology ventures for the nation’s venture community. Our inclusion among this elite group underscores the promise of our cutting-edge cancer therapeutic platform, which engages the innate immune system to target and eliminate malignant cells.

Being chosen to pitch at the Southeast Venture Showcase highlights Annate Bitherapeutics’ innovative work in developing effective, next-generation treatments that address critical challenges in oncology. As we prepare for this milestone occasion, we look forward to sharing our vision, expanding our professional network, and catalyzing future strategic partnerships. For more information about the Showcase and to stay updated on event developments, visit the official website at Southeast Venture Showcase.

Georgia CTSA Awards Lesinski / Hajduk Lab Funding for Developing Relevant Models for ApoL1 Based Therapies

2024-08-01T00:00:00+00:00

The Lesinski and Hajduk labs are proud to announce they have been awarded $50,000 from the Georgia Clinical & Translational Science Alliance (Georgia CTSA) to advance their groundbreaking work harnessing the human immune protein Apolipoprotein L1 (ApoL1) to selectively eliminate cancer cells. By developing bispecific antibodies (bsAb) that bind ApoL1 and cancer-specific targets such as BCMA or mesothelin, this research offers a promising new strategy against multiple myeloma and pancreatic cancers.

This project addresses key hurdles in translating complex antibody-based treatments into clinical practice. By developing physiologically relevant models, the Lesinski and Hajduk labs aim to accelerate the development of a potent, precise treatment option for patients with mesothelin-expressing cancers. Their collaboration, supported by the Georgia CTSA, underscores the pivotal role of innovative research and cross-institutional funding in driving progress toward next-generation cancer therapies.